GlassScriptPhysician profile
Dmitriy Kireyev
NPI 1003144528
$3,286.91
in general payments reported to CMS, 2019-2025
21 companies · $83.68 in 2025
The $83.68 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $358 · 2021: $543 · 2022: $473 · 2023: $768 · 2024: $547 · 2025: $83.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,396 · Education: $3.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,395.58 |
| Education | $3.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,070.55 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $407.34 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $375.85 | 2019-2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $238.96 | 2019-2024 | Farxiga, Wainua, Brilinta |
| Janssen Pharmaceuticals, INC | $237.70 | 2019-2022 | |
| Amgen INC. | $188.73 | 2019-2024 | Repatha |
| Novo Nordisk INC | $113.77 | 2020-2025 | Ozempic |
| Actelion Pharmaceuticals US, INC. | $109.04 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.73 | 2023 | Lifevest |
| Amarin Pharma, INC. | $72.89 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $67.28 | 2021-2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $56.80 | 2021-2023 | Verquvo |
| Baxter Healthcare | $51.71 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.85 | 2019 | |
| Esperion Therapeutics, INC. | $44.85 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $26.09 | 2022 | |
| Cvrx, INC. | $23.73 | 2023 | Barostim Neo System |
| Heartflow, INC. | $22.90 | 2023 | Ffrct |
| Lexicon Pharmaceuticals, INC. | $21.40 | 2023 | Inpefa |
| Cmp Pharma, INC. | $19.06 | 2023 | Atorvaliq, Carospir, Norliqva |
| Alnylam Pharmaceuticals INC. | $18.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitriy Kireyev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.